.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Breast Cancer

Payer Perspective of Coverage on Cancer Therapies

The role of PI3 kinase inhibition in various settings in metastatic breast cancer and a payer perspective on differentiating breast cancer at various stages of disease progression.

Payer Coverage on Repeat Biopsy in MBC

Testing patients who have received CDK4/6 inhibitors in metastatic breast cancer (MBC) as well as testing patients with ctDNA upon disease progression with a single gene test versus NGS.

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

November 23rd 2021, 2:00pm

Article

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

Florida Cancer Specialists & Research Institute Breast Cancer Partnership Receives National Accreditation

October 26th 2021, 6:14pm

Article

Collaboration with community partners recognized for patient care excellence.

Dr Funmi Olopade on WISDOM: When You Ask Women to Participate, They Sign Up

October 20th 2021, 2:00pm

Video

The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She is an expert on understanding the etiology and genomic basis of cancer progression in diverse populations and has published extensively on both genetic and non-genetic risk factors for breast cancer. She discussed overcoming early challenges of low enrollment of Black women in the study.

What We're Reading: RWE Finds Pfizer, Moderna Vaccines Highly Effective; Signs of COVID-19 Surge; Lawsuit Threatens Free Preventive Care

March 30th 2021, 3:00pm

Article

The Pfizer and Moderna COVID-19 vaccines were shown to be 90% effective in preventing infection in a real-world setting; Biden administration urges states to pause reopening plans amid signs of COVID-19 surge; a lawsuit seeks to end the requirement that preventive services be provided free of charge to Americans.

What We’re Reading: COVID-19 Screening Guidance; Eli Lilly Verzenio Results; Long-Haul Symptom Improvement

March 17th 2021, 2:24pm

Article

The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.

As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19

February 15th 2021, 8:00pm

Article

The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.

A Cue-to-Action Pilot Project to Increase Screening Mammography

February 8th 2021, 5:00pm

Article

A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.

Mental Illness May Predispose Women With Breast Cancer to Higher Mortality

January 19th 2021, 10:24pm

Article

Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.

Dr Alexey Aleshin Discusses Lingering Struggles in Pinpointing Biomarkers for Breast Cancer Reoccurrence

January 13th 2021, 2:00pm

Video

Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.

Researchers Identify Possible Source of Inflammatory Response Disparity in Black, White Women With Breast Cancer

January 11th 2021, 9:20pm

Article

A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.